SeaStar Medical's QUELIMMUNE Therapy Shows Strong Real-World Survival Data in Pediatric AKI
Event summary
- SeaStar Medical published real-world data in Pediatric Nephrology showing 76% survival at Day 28 and 60 for QUELIMMUNE therapy in pediatric AKI patients, with 71% survival at Day 90.
- No device-related adverse events or infections were reported in the first 21 patients treated with QUELIMMUNE.
- FDA reduced the mandated target for the SAVE Registry from 300 to 50 patients after reviewing initial data.
- QUELIMMUNE therapy has been adopted by top-rated children’s medical centers across the U.S.
- The therapy showed a 60% survival rate at Day 90 for patients concomitantly treated with ECMO.
The big picture
SeaStar Medical's QUELIMMUNE therapy is gaining traction in the pediatric AKI space, with real-world data validating its clinical benefits. The reduction in the SAVE Registry patient target by the FDA suggests growing confidence in the therapy's safety and efficacy. This positions SeaStar Medical to potentially expand its market reach, particularly as it advances its adult-focused NEUTRALIZE-AKI trial.
What we're watching
- Clinical Validation
- How the real-world data from the SAVE Registry will impact the broader adoption of QUELIMMUNE therapy in pediatric AKI patients.
- Regulatory Dynamics
- Whether the reduced patient target for the SAVE Registry will accelerate the therapy's market penetration.
- Market Expansion
- The pace at which SeaStar Medical can transition its technology to adult patients through the NEUTRALIZE-AKI trial.
Related topics